by Market Overview:
The global U.S. sucralfate market is estimated to be valued at US$ 296.2 million in 2022 and is expected to exhibit a CAGR of 3.1% over the forecast period of 2018-2026, as highlighted in a new report published by Coherent Market Insights. The market is witnessing growth due to the increasing prevalence of gastrointestinal disorders, such as peptic ulcers and gastroesophageal reflux disease (GER. These disorders are becoming increasingly common, resulting in a higher demand for sucralfate as a medication to treat these conditions. Despite the growth prospects, the market faces obstacles such as stringent regulatory approvals and the availability of alternative treatment options.
Market Key Trends:
One key trend driving the U.S. sucralfate market is the rising adoption of combination therapies for gastrointestinal disorders. Healthcare providers are increasingly prescribing sucralfate along with proton pump inhibitors (PPIs) or H2-receptor antagonists to achieve more effective results in treating conditions such as peptic ulcers. This combination therapy helps in reducing acidity and protecting the gastric mucosa, providing enhanced relief to patients. For instance, a study published in the European Journal of Gastroenterology & Hepatology found that the combination of sucralfate and PPIs showed superior healing rates in patients with peptic ulcers compared to PPI monotherapy.
Segment Analysis:
The U.S. sucralfate market is segmented based on the dosage form, including tablets and suspension. Among these segments, tablets dominate the market due to their ease of administration and longer shelf life compared to suspensions. Tablets also offer the advantage of convenient storage and transportation, making them a preferred choice for both healthcare providers and patients. Moreover, tablets are widely available in various strengths, allowing for precise dosage adjustments based on individual patient needs. These factors contribute to the dominance of tablets in the U.S. sucralfate market.
Key Takeaways:
Market Size Related Content:
The U.S. Sucralfate Market Demand is expected to witness high growth, exhibiting a CAGR of 3.1% over the forecast period. This growth can be attributed to the increasing prevalence of gastrointestinal disorders, such as peptic ulcers and GERD. The rising adoption of combination therapies, such as sucralfate with PPIs or H2-receptor antagonists, further boosts the market.
Regional Analysis:
The U.S. dominates the sucralfate market in North America and is expected to continue its dominance throughout the forecast period. The region has a high prevalence of gastrointestinal disorders, coupled with well-established healthcare infrastructure and high healthcare spending. These factors contribute to the fastest growth rate in the U.S. sucralfate market in North America.
Key Players:
Key players operating in the U.S. sucralfate market include Teva Pharmaceutical Industries Ltd., Allergan plc, Vertice Pharma LLC, and Pharmaceutical Associates Inc. These players focus on strategies such as mergers and acquisitions, product launches, and collaborations to strengthen their market presence and gain a competitive edge. For instance, Vertice Pharma LLC acquired VistaPharm Inc., a major manufacturer and marketer of generic pharmaceutical products, to expand its product portfolio and enhance its market position.
In conclusion, the U.S. sucralfate market is driven by the increasing prevalence of gastrointestinal disorders, leading to a higher demand for medications such as sucralfate. The rising adoption of combination therapies and the dominance of tablets in the market are key trends shaping its growth. The market is expected to continue expanding at a steady pace, with the U.S. maintaining its position as the leading market in North America. Key players in the market are actively adopting strategies to strengthen their market presence.
